OCT Consulting, a division of OCT Group, offers Pharma / Biotech / Medtech / Nanomed companies to receive investments into their Phase 1-4 clinical stage development programs / projects.
We collaborate with a number of life science institutional and corporate investors from Russia and abroad interested in financing projects/companies developing novel therapeutics (pharmaceuticals and biologics), nutraceuticals, platform technologies, diagnostics, which have high commercial potential and social benefit. General investment amounts: up to $5 million, $5-10 million, $10-25 million, $25-50 million, could be higher. Our partners work on condition of co-investing or act as lead investors; raise funds; look for regional in-licensing opportunities.
| Developer | R&D project | Investments required | Investor | Financial instruments | Focus | |
|
Medtech (Germany) |
Drug eluting stents. Clinical trials, production, marketing in Russia |
From 10m USD |
 Avrio Pharm |
Negotiable. Regional in-licensing |
Clinical trials financing in exchange for regional license (CIS region) |
|
|
Biotech (Switzerland) |
Phase II Alzheimer disease |
12-15m USD. Out-liсensing (regional, global) |
Venture co-financing from 10m USD. Equity (50%-1 share), loans, leasing |
Nanomed projects. Production in Russia. Annual sales in 5 years - 6m EUR as a min |
||
|
Biotech (Russia) |
Plant-expressed production of vaccinies / technology transfer to Russia. From preclinical to markerting |
From 40m USD (R&D) |
Funds raising |
CIS region |
||
|
Biotech (Germany) |
Phase III oncology projects (multiple myeloma, endometrial cancer) |
Regional out-liсensing (Russia) |
Fund of funds (Switzerland) |
10-30m EUR on average. Equity, loans |
Nutrition, Prevention, botanicals, FSMP, OTC, medical food, drugs (GI), etc. |
|
|
Biotech (Sweden) |
Phase II–III COPD |
10m EUR (Phase 2 program) + 26m EUR (Phase 3 program) |
Venture Fund (Russia) |
Up to 10m USD in equity |
Early stage. Oncology, CNS, metabolic, infectious |
|
|
Biotech (US) |
Phase III Oncology (breast, NSCLC, others) |
70m USD |
VC & PE fund (Switzerland) |
3-7m EUR in equity |
Preclinical, Phase I–II Clinical. Oncology |
|
|
Biotech (Germany) |
Phase II Prostate cancer |
15-20m USD |
Big Pharma (US) |
In-lisensing |
Early stage. mAbs, biological targets, biomarkers. Alzheimer disease, HIV, Diabetes, Asthma, Oncology. First and best in class |
|
|
Biotech (US) |
Nanomed oncology. Early stage (preclinical, PoC) |
6m USD institutional investments |
VC fund (US) |
8-12m USD in equity on average |
Mostly early stage. Therapeutics, Medical devices |
|
|
Biotech (UK) |
Phase I (oncology: SCLC, colorectal, others) |
Out-lisensing |
PE firm (US) |
10m USD as a min. Usually - from 30m USD |
Oncology, metabolic, others. Mostly late stage |
|
|
Biotech (Sweden) |
Phase II–III oncology (breast, prostate, ovarian cancer, NSCLC, others) |
Regional out-liсensing (CIS), equity and project financing |
PE fund (UK/US) |
Negotiable. In-licensing (Russia) |
Late stage. Biologics, Pharmaceuticals |
|
|
Biotech (US) |
Solid tumors. IND submission, Phase I |
15m USD |
State fund (Russia) |
35k-350k USD per project |
Early stage. Russian. Small business |
|
|
Biotech (Spain) |
Lung and pancreatic cancer. Preclinical, Phase I–II |
8,5m EUR in equity |
Pharma (US) |
In-lisensing |
Orphan, Oncology, CNS, Respiratory, Drug Delivery. Phase III–IV |
|
|
Biotech (Austria) |
Allergy vaccines. Phase II |
10m EUR of institutional or PE investments |
Big Pharma (US) |
In-lisensing |
Preclinical, Phase I–III. Oncology |
|
|
Biotech (Switzerland) |
Brain tumor. Preclinical |
8m USD in equity |
Big Pharma (UK) |
In-lisensing |
Orphan (except oncology) |
|
|
Biotech (Switzerland) |
Medical devices to treat rhinitis, diabetic foot ulcers |
5m CHF in PE |
Pharma (Canada) |
In-lisensing |
Pain drugs. Late stage |
|
|
Biotech (Spain) |
Preclinical Pain, Phase II Lupus, Phase I Oncology |
Out-lisensing |
PE firm (US) |
20-25m USD per project. Equity |
Phase III. Oncology, metabolic, cardiovascular, ophthalmology, dermatology |
|
|
Biotech (Israel) |
Phase II Stroke, Phase I Migrain |
6-8m USD |
Pharma (US) |
Equity financing. In-lisensing |
Early stage. Ophthalmology |
|
|
Biotech (Ireland) |
Phase II Colorectal cancer |
12m EUR of project financing |
PE firm (US) |
Project financing. 20-50m USD on average. Royalties contracts |
Clinical stage projects. Biopharmaceuticals, Medical devices |
|
|
Biotech (US) |
Phase II Oncology (breast, ovarian, endometrial) |
10m USD |
Pharma (Russia) |
Negotiable. In-licensing |
Phase II–III clinical trials financing in exchange for regional license (CIS ). Autoimmune, oncology, metabolic, intensive care, hospital antibiotics |
|
|
Biotech (France) |
Drug delivery platform (nanoencapsulation), protein delivery platform (microsheres), Phase I improved Paclitaxel |
350k EUR by Sep-2011 (first round), 2,5m EUR (second round) |
Big Pharma (US) |
In-lisensing |
Oncology, CNS, pain, immunology, renal diseases, ophthalmology. Phase II–III |
|
|
Biotech (France) |
Phase II Type 2 diabetes |
30m EUR. Global out-lisensing |
VC & PE firm (UK) |
5-15m USD per project, 30-40m per company |
Phase I–II. All areas (except diabetes, psychiatry) |
|
|
Biotech (Canada) |
Phase I–II Alzheimer disease, Phase I–II CVD (atherosclerosis, others) |
50m USD in equity. Regional out-liсensing (BRIC) |
VC firm (Switzerland) |
Negotiable |
Medical devices. European region |
|
|
Biotech (France) |
Phase II Prostate cancer, Phase IPsoriasis |
12m EUR in equity. Out-lisensing |
PE fund (US/Japan) |
Up to 5m per company |
EU, US region. Early stage companies. Therapeutics, vaccines, diagnostics, platform technologies. Nephrology, immunology, inflammatory, CNS, cardiovascular, etc. |
|
|
Biotech (US) |
Best in class. IBS Phase II–III, IBD Phase 1/2 |
50m USD |
PE firm (US) |
5-20m USD in equity |
Phase II–III. Pharmaceuticals, Nutrition products (except gene therapy, cell therapy, diabetes, cardiovascular) |
|
|
Biotech (Germany) |
Leukemia, solid tumors (mAbs) |
1,5m EUR of seed equity investments |
PE Fund (Ukraine) |
15-40m USD |
Phase III–IV clinical and marketing stage companies. Russia, Ukraine, Moldova, Belarus |
|
|
Biotech (Germany) |
Phase I–II Psoriasis, non-Hodgin's lymphoma |
5m EUR (Phase I), 15m EUR (Phase II). Regional out-liсensing (CIS) |
State VC firm (Russia) |
Up to 10m USD. Equity |
Russian companies. Biopharmaceuticals, Medical devices. Preclinical, Phase I–II Clinical |
|
|
Biotech (Spain) |
Phase I–II Calcium disorders (osteoporosis, kidney, heart diseases). Botanical drug |
6-12m EUR |
Business Angels (Russia) |
Negotiable |
Medical devices |
|
|
Biotech (Israel) |
Phase I–II HPV. Botanical drug |
14m EUR of PE investments. Out-lisensing |
PE & VC fund (Belgium) |
8-16m USD per company |
Autoimmune, musculuskeletal, eye, infectious diseases. Early stage. EU region |
|
|
Biotech (Austria) |
Phase I–III Parkinson disease, atherosclerosis |
50m EUR (2011-2014), in total 100m EUR (2011-2017) in equity |
Pharma (Germany) |
In-lisensing |
Early mAbs |
|
|
Biotech (UK) |
Phase II Oncology (NSCLC, colorectal) |
9m EUR in equity |
Medtech (UK) |
In-lisensing |
Orthopedics, trauma, reconstruction |
|
|
Biotech (France) |
Phase I Alzheimer disease |
4m EUR |
Pharma (US) |
In-lisensing (regions: US, Canada) |
Phase II–III. Cardiovascular, depression, hospital products |
|
|
Biotech (UK) |
Phase I Duchenne Muscular Dystrophy (DMD) |
3m EUR of project financing |
Fund (Denmark) |
Project grants |
Phase II-III, preferably in orphan diseases excluding oncology, CNS, metabolic and cardiovascular diseases |
|
|
Biotech (UK) |
Phase II–III Dry eye |
15m USD. Regional out-liсensing (CIS) |
Pharma (CIS) |
In-licensing |
Cardiology, neurology, gastroenterology, urology-gynecology, oncology, biosimilars; tenecteplase, alteplase, josamycin |
|
|
Biotech (US) |
Neurodegenerative disorders (Alzheimer, Huntington, etc.). Preclinical-clinical studies. Peptoid analog of beta-amyloid preventing fibrillation of amyloids and exhibiting antineurogenerative and neuroptotective effects |
Negotiable |
PE firm (UK) |
Up to 5m GBP per company |
UK region. Drugs - any phase (Phase II is more preferable); medical devices. Special interest to ophthalmology |
|
|
Biotech (Israel) |
Oncology (incl. nanomed) projects |
Out-licensing |
VC Fund (Germany) |
Equity financing |
Medical devices |
|
|
Pharma (US) |
Preclinical-Phase II-III CNS and oncology |
Out-licensing |
VC firm (Canada) |
20-25m in equity for 10-12 years |
Early stage or Ph II-III in EU; Medical devices. Antibody technologies, next generation, peptide, small molecules, nanoparticle delivery; oncology, liver fibrosis, infectious (gram negative), GI, cardio, metabolic |
|
|
Biotech (Switzerland) |
Phase III Asthma |
70m USD |
Pharma (US) |
In-licensing |
CNS, Parkinson, epilepsy; inhalation devices in CNS |
|
|
Biotech (Germany) |
Early stage CNS |
Equity and project financing |
Pharma (US) |
In-licensing |
Phase III CNS, MS, depression |
|
|
Biotech (Spain) |
Phase I Oncology |
5m USD (project or equity financing) |
Pharma (Canada) |
In-licensing |
Cardiovascular, CNS , infectious , cancer, immunological disorders; fibrosis and neurodegeneration |
|
|
Biotech (US) |
Phase I-II CLL, NHL, RA |
30-40m USD in equity; out-licensing |
PE group (France) |
4m EUR per seria, 10m EUR per EU company, per 3-8 years. 10-30% of equity share |
Drugs, medical devices, diagnostics. Oncology, ophthalmology, GI, metabolic. Early stage - Phase III |
|
|
Biotech (US) |
Phase II oncology |
20m USD in equity (individual investors) |
Biotech (US) |
In-licensing |
Early stage oncology |
|
|
Biotech (US) |
Phase II-III MDR TB, |
20-25m USD in equity |
To be updated | |||
|
Biotech (UK) |
cGMP, tox studies, Phase I Colorectal cancer, combination in chemotherapy (Irinotecan) |
8,5m GBP |
||||
| To be updated |
|
|
For additional questions concerning investment opportunities, please contact Ms. Ekaterina Mochalova, Business Development Manager at emochalova@oct-clinicaltrials.com or +7 (921) 915-23-17